Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for ABK3376, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). This drug is co-developed with Allist Pharmaceuticals Inc., (SHA: 688578), and is intended for the treatment of non-small cell lung cancer (NSCLC) with EGFR-C797S resistance mutation.
In a strategic move last year, in March, Allist Pharma entered into a licensing agreement with Abbisko, securing exclusive rights to research, develop, manufacture, use, and market ABK3376 in Greater China, which includes the Chinese mainland, Hong Kong, Macau, and Taiwan. Allist Pharma retains an option to potentially expand the territory of this agreement globally, contingent upon fulfilling certain conditions. The company plans to develop ABK3376, also known as AST2303, specifically for NSCLC patients carrying dual site mutations of EGFR L858R+C797S or Del19+C797S, who have developed resistance to treatment with third-generation EGFR TKIs.- Flcube.com
